The FDA has approved the menin inhibitor revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation in certain adult and pediatric patients 1 year and older. The U.S. Food and...
The FDA approved the BCMA-targeted antibody-drug conjugate belantamab mafodotin-blmf as part of a combination therapy for adults with refractory or recurrent multiple myeloma. The U.S. Food and Drug Administration (FDA) has approved belantamab mafodotin-blmf...
The FDA approved cemiplimab-rwlc as an adjuvant therapy for patients with cutaneous squamous cell carcinoma at high risk of recurrence. The U.S. Food and Drug Administration (FDA) has approved cemiplimab-rwlc (Libtayo) for use after...
The FDA has approved the DNA-damaging agent in combination with immunotherapy for patients whose cancers have not progressed after first-line therapy. The U.S. Food and Drug Administration (FDA) has approved lurbinectedin (Zepzelca) in combination...
The FDA has approved imlunestrant for certain patients with advanced ESR1-mutated breast cancer that has progressed following previous endocrine therapy. The U.S. Food and Drug Administration (FDA) has approved imlunestrant (Inluriyo) for the treatment...
The FDA approved pembrolizumab and berahyaluronidase alfa-pmph as an injectable therapy for multiple tumor types. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for subcutaneous (under the...
FDA expands selumetinib approval to include pediatric patients as young as 1 year with inoperable plexiform neurofibromas. The U.S. Food and Drug Administration (FDA) has approved selumetinib (Koselugo) granules and capsules for pediatric patients...
The FDA has approved a delivery system that, once inserted into the bladder, delivers a local dose of the drug gemcitabine. The U.S. Food and Drug Administration (FDA) has approved a gemcitabine intravesical system...
The FDA has approved zongertinib for patients with unresectable or metastatic non-squamous non-small cell lung cancer that has HER2 tyrosine kinase domain mutations and has undergone prior treatment. The U.S. Food and Drug Administration...
The FDA has approved the first-in-class therapeutic dordaviprone for certain adult and pediatric patients with H3 K27M-mutated diffuse midline glioma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to dordaviprone (Modeyso)...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More